Biotech Asset Strategy

Two professionals in a high-rise office discussing a molecular model and data on a tablet. Overlaid text asks: "Can this be transferred, scaled, and commercialized without introducing new risk?"

LAI Licensing in Central Nervous System Disorders: Where Execution Risk Sits in 2026

Interest in long-acting injectables (LAIs) for Central Nervous System (CNS) disorders has returned to business development and investment discussions for […]

LAI Licensing in Central Nervous System Disorders: Where Execution Risk Sits in 2026 Read More »

A modern boardroom table featuring a sleek white medical inhaler device, a laptop displaying pharmaceutical data charts, and a tablet showing a strategic licensing flow chart for 2026.

Inhalation Drug Licensing in 2026: Why Execution-Ready Assets Are Queitly Winning

Article / SEQOVA

For years, inhalation drug licensing has been misunderstood. It wasn’t deprioritized because it failed scientifically. It was deprioritized because the

Inhalation Drug Licensing in 2026: Why Execution-Ready Assets Are Queitly Winning Read More »